


AMENDMENT TO THE CLAIMS

Please amend the claims as follows:

1. (currently amended) A compound of formula I below, and physiologically acceptable salts, comprising:



wherein,

the "A" ring atoms are selected from ~~of compound formula I comprise~~ carbon and 0 to 2 nitrogen heteroatoms;

Ar is an aromatic ring, an aromatic ring having ~~comprising~~ at least one substituent group, a heteroaromatic ring, a heteroaromatic ring having ~~comprising~~ 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring having ~~comprising~~ at least one substituent group;

R is selected from H, OH, OCH₃, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R' is selected from H, OH, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R" is Y-D₁-D₂-T₂,

Y is optionally present and if present is selected from O, S, NH, N-alkyl, C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, and a substituent group;

R''' and R'''' are each independently selected from H, halogen, alkyl, alkoxy and a substituent group;

with the proviso that,

when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R''' is hydrogen, and R'''' is hydrogen, then R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R''' and R'''' are hydrogen, R" can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when R" is C(CH₃)₂(CH₂)₅CH₃, R₂ and R₄ are methyl, then R' and R" can not be H, OH or OCH₃.

2. cancelled

3. (previously presented) The compound of claim 1 wherein:

R''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy;

R'''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy; and

R'' is selected from -Y-D₁-D₂-T₂,

Y is selected from C(CH₃)₂, CH₂ and CH(CH₃),

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen and a substituent group.

4. (previously presented) The compound of claim 1 wherein:

R''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy;

R'''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy; and

R'' is -Y-D₁-D₂-T₂,

Y is selected from O, NH and N-alkyl,

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen and a substituent group.

5. (previously presented) The compound of claim 1 wherein:

R''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy;

R'''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy; and

R'' is -Y-D₁-D₂-T₂,

Y is optionally present and if present is selected from C=CH and C≡C,

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen and a substituent group.

6. (previously presented) The compound of claim 1 wherein:

R''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy;

R'''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy; and

R'' is -Y-D₁-D₂-T₂,

Y is optionally present and if present is selected from a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,



D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen and a substituent group.

7. (previously presented) The compound of claim 1 wherein Ar is selected from an aromatic ring having 5 or 6 ring members and a heteroaromatic ring having 5 or 6 ring members.

8. (previously presented) The compound of claim 1 wherein Ar is selected from one of the structures:



and,

the Ar aromatic ring structure comprises 0 to 3 heteroatoms as ring members;

R1, R2, R3, R4 and R5 are each independently selected from H, OH, NH₂, halogen,

Appl. No.: 10/647,550


Response to Office communication dated: 06/08/2006

Attorney Docket: UCONEN/206/US

N₃, NO₂, NCS, C(halogen)₃, CHO, OAc, OCH₃, OC₂H₅, CH₂OH, CH₂CH₂OH, CH₂CH₂CH₂OH, CN, C(=O)CH₃, COOH, COOCH₃, COOC₂H₅, COOCH(CH₃)₂, NHCOCH₃, SCH₃, SC₂H₅, NHCH₃, CH₂NH₂, CH₃, C₂H₅, C₃H₇, C₂H₃, ethynyl, alkoxy, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl, alkylsulfonyl, methylene dioxy and a substituent group.


9. (previously presented) The compound of claim 1 wherein Ar is selected from 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 1-, 2- or 3-morpholinyl, 1-, 2- or 3-thiomorpholinyl, 1-, 2- or 3-azetidyl, 1-, or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on any available ring carbon thereof by alkyl; or any above group unsubstituted on one or more nitrogen atoms, or any above group substituted on one or more nitrogen atoms independently by an alkyl, benzyl, lower-alkoxybenzyl or benzhydryl group; adamantyl; a carbocyclic ring, a substituted carbocyclic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, a bicyclic ring, a substituted bicyclic ring, a heterobicyclic ring, a substituted heterobicyclic ring, a polycyclic ring, a substituted polycyclic ring, a heteropolycyclic ring or a substituted heteropolycyclic ring.

10. (previously presented) The compound of claim 1 wherein Ar is selected from:



G is selected from H, OH, NH₂, halogen, N₃, NO₂, NCS, CF₃, CHO, OAc, OCH₃, OC₂H₅, CH₂OH, CH₂CH₂OH, CH₂CH₂CH₂OH, CN, C(=O)CH₃, COOH, COOCH₃, COOC₂H₅, COOCH(CH₃)₂, NHCOCH₃, SCH₃, SC₂H₅, NHCH₃, CH₂NH₂, CH₃, C₂H₅, C₃H₇, C₂H₃, ethynyl, alkoxy, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl, alkylsulfonyl and methylene dioxy.

11. (currently amended) A pharmaceutical preparation comprising a therapeutically effective amount of at least one compound of formula I below, and physiologically acceptable salts thereof:



wherein,

the "A" ring atoms are selected from of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;

Ar is an aromatic ring, an aromatic ring having ~~comprising~~ at least one substituent group, a heteroaromatic ring, a heteroaromatic ring having ~~comprising~~ 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring having ~~comprising~~ at least one substituent group;

R is selected from H, OH, OCH₃, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R' is selected from OH, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R" is Y-D₁-D₂-T₂,

Y is optionally present and if present is selected from O, S, NH, N-alkyl, C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, and a substituent group;

R''' and R'''' are each independently selected from H, halogen, alkyl, alkoxy and a substituent group;

with the proviso that,

when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R''' is hydrogen, and R'''' is hydrogen, then R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R''' and R'''' are hydrogen, R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when R'' is C(CH₃)₂(CH₂)₅CH₃, R₂ and R₄ are methyl, then R' and R'' can not be H, OH or OCH₃.

12. cancelled

13. (previously presented) The pharmaceutical preparation of claim 11, wherein:

R''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy;

R'''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy; and

R'' is -Y-D₁-D₂-T₂,


Y is optionally present and if present is selected from O, S, NH, N-alkyl, C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen and a substituent group.

14. (currently amended) A method of stimulating a cannabinoid receptor in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of at least one compound of formula I below, and physiologically acceptable salts thereof:



wherein,

the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;

Ar is an aromatic ring, an aromatic ring having comprising at least one substituent group, a heteroaromatic ring, a heteroaromatic ring having comprising 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring having comprising at least one substituent group;

R is selected from H, OH, OCH₃, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R' is selected from OH, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R'' is Y-D₁-D₂-T₂,

Y is optionally present and if present is selected from O, S, NH, N-alkyl, C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic

ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, and a substituent group;

R''' and R'''' are each independently selected from H, halogen, alkyl, alkoxy and a substituent group;

with the proviso that,

when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R''' is hydrogen, and R'''' is hydrogen, then R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R''' and R'''' are hydrogen, R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when R'' is C(CH₃)₂(CH₂)₅CH₃, R₂ and R₄ are methyl, then R' and R'' can not be H, OH or OCH₃.

15. (previously presented) The method of claim 14 wherein:

R''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy;

R'''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy; and

R'' is -Y-D₁-D₂-T₂,

Y is optionally present and if present is selected from O, S, NH, N-alkyl, C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,


D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a

heteroaromatic ring, a heterocyclic ring, H, OH, halogen and a substituent group.

16. (currently amended) A method of selectively stimulating CB2 cannabinoid receptors in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of at least one compound of formula I below, and physiologically acceptable salts thereof:



wherein,

the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;

Ar is an aromatic ring, an aromatic ring having ~~comprising~~ at least one substituent group, a heteroaromatic ring, a heteroaromatic ring having ~~comprising~~ 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring having ~~comprising~~ at least one substituent group;

R is selected from H, OH, OCH₃, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R' is selected from OH, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R'' is $Y-D_1-D_2-T_2$,

Y is optionally present and if present is selected from O, S, NH, N-alkyl, $C=CH$, $C\equiv C$, CH_2 , $CH(CH_3)$, $C(CH_3)_2$, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D_1 is optionally present and if present is alkyl,

D_2 is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T_2 is optionally present and if present is selected from an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, and a substituent group;

R''' and R'''' are each independently selected from H, halogen, alkyl, alkoxy and a substituent group;

with the proviso that,

when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R''' is hydrogen, and R'''' is hydrogen, then R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R''' and R'''' are hydrogen, R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when R'' is $C(CH_3)_2(CH_2)_5CH_3$, R_2 and R_4 are methyl, then R' and R'' can not be H, OH or OCH_3 .

17. (previously presented) The method of claim 16, wherein:

R''' is selected from H, halogen, $C(\text{halogen})_3$, lower alkyl and alkoxy;

R'''' is selected from H, halogen, $C(\text{halogen})_3$, lower alkyl and alkoxy; and

R'' is $-Y-D_1-D_2-T_2$,

Y is optionally present and if present is selected from O, S, NH, N-alkyl,


C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen and a substituent group.

18. (currently amended) A method of treating a condition comprising administering to an individual or animal having the condition a therapeutically effective amount of at least one compound of formula I below, and physiologically acceptable salts thereof:



wherein,

the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;

Ar is an aromatic ring, an aromatic ring having ~~comprising~~ at least one substituent group, a heteroaromatic ring, a heteroaromatic ring having ~~comprising~~ 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring having ~~comprising~~ at least one substituent group;

R is selected from H, OH, OCH₃, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R' is selected from OH, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R'' is Y-D₁-D₂-T₂,

Y is optionally present and if present is selected from O, S, NH, N-alkyl, C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, and a substituent group;

R''' and R'''' are each independently selected from H, halogen, alkyl, alkoxy and a substituent group,

with the proviso that,

when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R''' is hydrogen, and R'''' is hydrogen, then R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R''' and R'''' are hydrogen, R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when R'' is C(CH₃)₂(CH₂)₅CH₃, R₂ and R₄ are methyl, then R' and R'' can not be H, OH or OCH₃.

19. (previously presented) The method of claim 18, wherein:

R''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy;

R'''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy; and

R'' is -Y-D₁-D₂-T₂,


Y is optionally present and if present is selected from O, S, NH, N-alkyl, C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen and a substituent group.

20. (currently amended) A method of providing a physiological response in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of at least one compound of formula I below, and physiologically acceptable salts thereof:



wherein,

the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;

Ar is an aromatic ring, an aromatic ring having ~~comprising~~ at least one substituent group, a heteroaromatic ring, a heteroaromatic ring having ~~comprising~~ 1 to 5 substituent

groups, a heterocyclic ring or a heterocyclic ring having comprising at least one substituent group;

R is selected from H, OH, OCH₃, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R' is selected from H, OH, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R'' is Y-D₁-D₂-T₂,

Y is optionally present and if present is selected from O, S, NH, N-alkyl, C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, and a substituent group;

R''' and R'''' are each independently selected from H, halogen, alkyl, alkoxy and a substituent group,

with the proviso that,

when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R''' is hydrogen, and R'''' is hydrogen, then R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R''' and R'''' are hydrogen, R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when R'' is C(CH₃)₂(CH₂)₅CH₃, R₂ and R₄ are methyl, then R' and R'' can not be H, OH or OCH₃.

21. (previously presented) The method of claim 20, wherein:

R''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy;

R'''' is selected from H, halogen, C(halogen)₃, lower alkyl and alkoxy; and

R'' is -Y-D₁-D₂-T₂,

Y is optionally present and if present is selected from O, S, NH, N-alkyl, C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,


D₁ is optionally present and if present is alkyl,

D₂ is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T₂ is optionally present and if present is selected from an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen and a substituent group.

22. (currently amended) A method of treating a condition selected from central and peripheral pain, neuropathy, neurodegenerative diseases including multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease; mental disorders such as schizophrenia and depression, endotoxic shock, hypotensive shock; or of modulating appetite; or of modulating the immune system; or of reducing fertility; or of treating diseases associated with motor function such as Tourette's syndrome; or of treating inflammation; or of providing neuroprotection; or of suppressing memory; or of producing peripheral vasodilation; or of treating epilepsy, glaucoma, nausea associated with cancer chemotherapy or nausea associated with Aids wasting syndrome comprising administering to an individual or animal having the condition a therapeutically effective amount of at least

one compound of formula I below, and physiologically acceptable salts thereof:



wherein,

the "A" ring atoms of compound formula I comprise carbon and 0 to 2 nitrogen heteroatoms;

Ar is an aromatic ring, an aromatic ring having ~~comprising~~ at least one substituent group, a heteroaromatic ring, a heteroaromatic ring having ~~comprising~~ 1 to 5 substituent groups, a heterocyclic ring or a heterocyclic ring having ~~comprising~~ at least one substituent group;

R is selected from H, OH, OCH₃, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R' is selected from H, OH, alkoxy, OCH₂CH₂OH, alcohol, NH₂, PO₃H, OPO₃H, OSO₃H, halogen, C(halogen)₃, SE₁, OE₁ and NE₁E₂,

E₁ and E₂ are each independently H or alkyl;

R'' is Y-D₁-D₂-T₂,

Y is optionally present and if present is selected from O, S, NH, N-alkyl, C=CH, C≡C, CH₂, CH(CH₃), C(CH₃)₂, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D_1 is optionally present and if present is alkyl,

D_2 is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T_2 is optionally present and if present is selected from an aromatic ring, a substituted aromatic ring, a heteroaromatic ring, a substituted heteroaromatic ring, a heterocyclic ring, a substituted heterocyclic ring, H, OH, halogen, and a substituent group;

R''' and R'''' are each independently selected from H, halogen, alkyl, alkoxy and a substituent group,

with the proviso that,

when Ar is 4-isopropyl pyridine or 4-isopropenyl pyridine, R''' is hydrogen, and R'''' is hydrogen, then R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when Ar is 4-isopropyl toluene or 4-isopropenyl toluene, and both R''' and R'''' are hydrogen, R'' can not be a straight or branched saturated alkyl having 1 to 20 carbon atoms;

when R'' is $C(CH_3)_2(CH_2)_5CH_3$, R_2 and R_4 are methyl, then R' and R can not be H, OH or OCH_3 .

23. (previously presented) The method of claim 22, wherein:

R''' is selected from H, halogen, $C(\text{halogen})_3$, lower alkyl and alkoxy;

R'''' is selected from H, halogen, $C(\text{halogen})_3$, lower alkyl and alkoxy; and

R'' is $-Y-D_1-D_2-T_2$,

Y is optionally present and if present is selected from O, S, NH, N-alkyl, $C=CH$, $C\equiv C$, CH_2 , $CH(CH_3)$, $C(CH_3)_2$, a carbocyclic ring having 4 to 6 ring members and a heterocyclic ring having 4 to 6 ring members with 1 or 2 heteroatoms,

D_1 is optionally present and if present is alkyl,

D_2 is selected from alkyl, NH, N-alkyl, O-alkyl, S-alkyl, a carbocyclic ring, a

Appl. No.: 10/647,550

Response to Office communication dated: 06/08/2006

Attorney Docket: UCONEN/206/US

bicyclic ring, a tricyclic ring, an aromatic ring and a heteroaromatic ring,

T_2 is optionally present and if present is selected from an aromatic ring, a heteroaromatic ring, a heterocyclic ring, H, OH, halogen and a substituent group.